Abstract: A laser capsule marking system and method may comprise at least two indexing wheels, a feeding mechanism, a laser marker, a first inspection system, a rejection subsystem, a reject verification sensor, and a collection device. The wheels are coaxial and have respective circumferential peripheries with multiple open pockets distributed thereabout. Each pocket is configured to releasably receive a pharmaceutical capsule doped with pigment particles reactive to laser light. The indexing wheels are configured to be incrementally rotated in alternating indexing fashion for transporting discrete arrays of respective pockets through a loading zone, an inspection zone, a marking zone, a reject zone, and an unloading zone. An actuatable reject block may be provided to simultaneously blow a rejected capsule from its pocket, and draw it in for transport to a rejection bin. Each circumferential periphery may be comprised of multiple arcuate shoes removably and replaceably secured to their respective indexing wheel.

Abstract: A medicine container and a method of forming the medicine container are described herein. The medicine container includes a bottle and a bottle cap removably connected to the bottle. A dose cup is disposed over the bottle cap, the dose cup having an opening defined by a perimeter. A tamper band is monolithically coupled to the perimeter of the dose cup. The tamper band is directly connected to the bottle by a destructively attached connection.

Abstract: A very simple, effective medication reminder used to designate the day of the week and the daily dosage number of the most recent medication dosage taken by the user (or alternatively the day of the week and the next dosage number to be taken). This invention can be used with medication containers of various sizes and shapes. It can be used over and over on the same pill bottle or it and be easily removed and placed on a new pill bottle. The device is placed on the exterior perimeter of the medication container and comprises a calendar and a marker assembly. The calendar shows the days of the week and is attached to the vertical side of the pill bottle using a weak adhesive. The marker assembly comprises an elastic band and a small tubular shaped sliding marker with the elastic band passing through an axial hole through the sliding marker.

Abstract: A breastfeeding nipple shield includes an extended molded adhesive flap surface and an adhesive strip on the extended molded surface attached to the rim of the areola shield portion to attach the breastfeeding nipple shield to the nursing mother's breast and retain portion in place. The adhesive flap may be elongated to distribute the load and prevent painful pulling on the breast. A molded feeding tube channel may allow a separate feeding tube to be unobtrusively inserted into the nipple opening. The feeding tube channel may be flanked by adhesive segments to secure the feeding tube in place.

Abstract: This invention relates to a transnasal tube assembly comprising a transnasal tube and an integrated tether for anchoring the transnasal tube, wherein the integrated tether is permanently fixed to the transnasal tube at a first fixation point, and wherein the integrated tether is reversibly fixable to the transnasal tube at a second fixation point.

Abstract: The present invention includes an indwelling tube having a plurality of projections extending outwardly from an exterior surface of the tube and a retention member designed to receive the tube. The retention member includes a projection passage to enable the retention member to receive and pass projections through the passage when the projection and passage are aligned so that the retention member can slide axially along the tube. When the projections and passage are out of alignment, the retention member can be secured between two projections. The present invention enables accurate placement of the retention member along the tube to aid in securing the tube at a desired depth in a patient's body. In a certain embodiment, the retention member may include a locking passage to receive and temporarily secure a projection to the retention member.

Abstract: Devices for inducing satiety in enterally fed patients are provided. In one aspect, an enteral feeding device is provided that includes a catheter tube and an expandable bladder secured to a distal end of the catheter tube. The expandable bladder is positionable within a body lumen of a patient for receiving and dispensing nutrients to the patient. In another aspect, a satiety-inducing device for continuously dispensing nutrients to a patient is provided that includes an enteral feeding tube and an expandable bladder secured to the feeding tube near a distal end of the feeding tube such that the expandable bladder is positionable within a body lumen of the patient. The expandable bladder expands upon receipt of nutrients to occupy a volume of the body lumen and contracts as nutrients are continuously dispensed to the patient.

Abstract: Embodiments can provide an expandable nasogastric intubation assembly, comprising a tube subassembly and an expander subassembly, comprising an inflatable balloon comprising a proximal expander component section and a distal expander component section wherein the proximal expander component section is located between the proximal end of the intubation assembly and the distal expander component section; wherein the distal expander component section is located between the distal end of the intubation assembly and the proximal expander component section; wherein the inflatable balloon is coupled to the tube subassembly, the proximal expander component section is configured to be inflated from an injection of fluid into at least one first opening located in the second passageway, and the distal expander component section is configured to be inflated by the injection of fluid into at least one second opening located in the second passageway.

Abstract: A modular pacifier assembly having a modular mouth guard assembly including a nipple. The modular mouth guard assembly includes a mouth guard shield and a removable mouth guard plate that interconnects into the mouth guard shield.

Abstract: A composite material including silanated filler and mixed polymerizable monomer, having a stable pasty property which keeps well and has a consistent usability. A composite material containing a silanated filler, a polymerizable monomer, and a polymerization initiator, and may be produced by a process which includes a mixed polymerizable monomer preparing step, a silanation step, a silanated filler preserving step, a composite material preparing step, a composite material preserving step, a composite material filling step, and a small quantity preserving container preserving step.

Abstract: The present invention provides: a cosmetic composition carrier comprising an integrated sponge having a layered structure; and a cosmetic product comprising the same. According to the present invention, the cosmetic composition carrier facilitates the filling of a cosmetic composition, can uniformly carry the cosmetic composition for a long time, discharges an appropriate amount of the cosmetic composition when using the cosmetic composition, and can maintain excellent durability for a long time even after the cosmetic composition is carried.

Abstract: The present invention relates to a microcomplex containing a modified nanoparticle adsorbed on a host microparticle and to a process to obtain it. The microcomplex is particularly useful for photoepilation. The present invention also relates to a composition containing the microcomplex and to the method for enhanced photoepilation based on the microcomplexes.

Abstract: The object of the present invention is an injectable sterile aqueous formulation, ready-to-use, resorbable, used for aesthetic purposes as a particulate, cohesive, viscoelastic gel comprising i) crosslinked hyaluronic acid, or one of its salts, at a concentration of between 1% and 4% (mass/volume); the crosslinking carried out providing the possibility of obtaining a gel based on crosslinked hyaluronic acid with a so-called cohesive structure, and ii) hydroxyapatite, at a concentration of between 5% and 60% (mass/volume), said hydroxyapatite being in the form of particles with an average size of less than or equal to 200 ?m; said injectable sterile aqueous formulation having viscoelastic properties such that tan ? at the frequency of 1 Hz is less than or equal to 0.60.

Abstract: Provided herein are microalgal skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel decolorized microalgal compositions useful for improving the health and appearance of skin. The invention also includes insoluble polysaccharide particles for application to human skin.

Abstract: The present invention relates to the use of an acid enriched in docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or DHA-derived EPA for manufacturing a drug for the treatment of processes that involve associated oxidative damage. In particular, it is for the treatment of processes associated with neurodegenerative, ocular, ischaemic and inflammatory pathology, atherosclerosis, with oxidative damage to DNA and with physical exercise.

Abstract: Personal care compositions that include a stable O/W emulsion, a stable retinoid, an oil, a fatty alcohol, and an emulsifier and methods of using such compositions to regulate a condition of mammalian keratinous tissue. By combining the oil and retinoid at a particular ratio in the personal care composition, the stability of the retinoid can be improved.

Abstract: A multicomponent packaging unit (kit-of-parts) for reductive decoloration of colored keratin fibers includes, presented separately from one another, a container (A) containing a cosmetic agent (a) and a container (B) containing a cosmetic agent (b). The agent (a) in container (A) (a1) includes one or more sulfinic acid derivatives from a particular group, (a2) includes one or more fatty constituents from the group of C12-C30 fatty alcohols, C12-C30 fatty acid triglycerides, C12-C30 fatty acid monoglycerides, C12-C30 fatty acid diglycerides, C12-C30 fatty acid esters, hydrocarbons and/or silicone oils, (a3) has a water content of at most 10.0% by weight, based on the total weight of the agent (a), the agent (b) in container (B) (b1) has a water content of at least 30.0% by weight, based on the total weight of the agent (b). Also, a method is for reductive decoloration of colored keratin fibers using the multicomponent packaging unit.

Abstract: Compositions and methods for amelioration of skin laxity and body contour are provided. Provided herein are compositions comprising a combination of peptides.

Abstract: Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is a process for the care of keratinous material(s), comprising the application or administration of HS8, or a composition comprising thereof, to keratinous material(s). The composition may be used to improve the condition of skin, such as smoothing the skin, restoring skin elasticity and firmness, or decreasing or preventing wrinkles, and may be formulated for topical or transdermal administration.

Abstract: The present invention provides an external-use liquid skin-conditioning composition that not only reduces the sticky and friction sensations caused by the inclusion of tranexamic acid, but also has a rich body without feeling slimy and softens the skin after use. The composition comprises (A) 0.5 to 5 mass % of at least one item selected from a group consisting of tranexamic acid and derivatives thereof and (B) 0.005 to 1.5 mass % of carboxymethylcellulose, has a viscosity of no greater than 500 mPa s at 30° C., and is transparent or semitransparent with an L value between 50 and 100 inclusive. Preferably the composition contains only carboxymethylcellulose as a thickener.

Abstract: A method of treating midface volume deficit in a person is provided. The method generally includes administering a dermal filler, such as a hyaluronic acid based dermal filler, in a sequence of injections that enhance effectiveness and/or duration of the filler. The method may include initially introducing a volume of the filler into at a zygomaticomalar region of the face prior to introducing one or more additional volumes of the filler into the anteromedial region and the submalar region, such that the duration of effectiveness of the treatment is improved, and less filler is required to achieve a desired correction.

Abstract: The present invention relates to a composition, preferably a cosmetic composition, in particular for coating keratin fibres such as the eyelashes, comprising: —an aqueous phase, —a lamellar phase L? formed by an aqueous phase-structuring surfactant system, said surfactant system comprising a content of surfactant(s) of greater than or equal to 15% by weight relative to the total weight of the composition, —at least one (poly)oxyalkylenated hydrophilic polymer present in a content of greater than or equal to 3% by weight of solids relative to the total weight of the composition, the hydrophilic polymer(s) having a weight-average molecular mass Mw ranging from 1500 to 500 000 g/mol. The present invention also relates to a process for coating keratin fibres.

Abstract: A tooth whitening product is provided. The tooth whitening product has a backing layer and a tooth whitening composition. The tooth whitening composition includes first and second water soluble polymers, water, and a tooth whitening agent, wherein the first water soluble polymer is polyethelene oxide and the second water soluble polymer is polyvinyl alcohol.

Abstract: Hairstyling compositions which provide the user with continuous wave frizz-free hairstyling using only low heat (such as that applied by a blow dryer) and a round hair brush as well as a natural feel to the hair is disclosed. The compositions incorporate a mixture of two and preferably three polymers, those polymers including an organopolysiloxane graft polymer, a graft polymer comprising polyacrylate (such as polyacrylate-32), and optionally a water-soluble silicone polymer (such as bis-PEG-8-dimethicone). The method of using these compositions to provide the desired hairstyles is also disclosed.

Abstract: In a first aspect, there is provided a topical composition for moisturizing the skin, including a hemp seed oil from about 70 percent to about 85 percent; and a pomegranate seed oil from greater than zero to about 10 percent. In a second aspect, there is provided a topical composition for the body, including a hemp seed oil from about 70 percent to about 90 percent; a pomegranate seed oil from about 1 percent to about 10 percent; and an essential oil from about 1 percent to about 5 percent. In other aspects, there are methods for treating various physical conditions. In some aspects, there are topical compositions for hair, beard, after-shave, sunscreen, lip moisturizer, and insect repellant.

Abstract: A new natural oil personal care composition and system for treating damaged hair and/or supporting healthy hair and healthy hair growth. The composition comprises a blend of natural oils including Jamaican black castor oil, and one or more of natural sweet almond oil (preferably unrefined), pure avocado oil, and hemp seed oil (preferably unrefined). The oils are preferably organic. The composition is useful for repairing damaged, depleted and/or thinning hair due to various factors, including inadequate nutrition or overproduction of sebum, which can result in hair loss. The composition is also useful for repairing dry, frizzy, oily, dull (low shine), and brittle hair that has been naturally damaged by the elements (e.g. the sun, heat, wind, and/or cold), by wearing head gear or hair accessories that create friction with the hair surface (e.g. helmets, hair elastics and hair bands), by inappropriate or overuse use of hair styling tools (e.g.

Abstract: A method of improving the appearance of periorbital dyschromia by identifying a target portion of skin in the periorbital region of a person that exhibits periorbital dyschromia and applying a personal care composition to the target portion of skin during a treatment period. The personal care composition includes an effective amount of Type I active, an effective amount of a Type II active, and a dermatologically acceptable carrier. The treatment period is of sufficient length for at least one of the actives to improve the appearance of the periorbital dyschromia.

Abstract: The present invention provides stable antioxidant cosmetic formulations for topical use comprising green tea extract in combination with additional active compounds having the surprising ability to exert antioxidant effect on the skin, the use stable antioxidant cosmetic formulations, as well as a method for reducing and/or preventing oxidative stress in keratinous tissues.

Abstract: Disclosed is an alcoholic extract of aerial parts of Anthyllis vulneraria, method for obtaining same, a cosmetic or dermatological composition containing same, as well as the cosmetic and dermatological uses thereof, in particular in depigmenting the skin.

Abstract: Disclosed is a method of treatment of a disease associated with abnormal protein aggregation comprising parenterally administering pharmaceutical formulations comprising trehalose. Also disclosed is an injectable aqueous pharmaceutical formulation comprising a therapeutically effective amount of trehalose.

Abstract: Disclosed are methods of subcutaneous delivery of a drug or a therapeutic agent to a subject comprising administering to said subject a tumescent composition comprising: (a) the drug or the therapeutic agent, wherein a tumescent concentration of the drug is simultaneously: 1) below a threshold for local, subcutaneous tissue toxicity, 2) above a threshold for positive local therapeutic effect, and 3) above a concentration achievable by intravenous (IV), intramuscular (IM) or oral (PO) delivery; (b) a vasoconstrictor; and (c) a pharmaceutically acceptable carrier. Some embodiments relate to a method of treating or preventing sepsis or Systemic Inflammatory Response Syndrome (SIRS) in a subject. Some embodiments relate to a tumescent solution for treating a localized viral infection, e.g., varicella-zoster (shingles), the tumescent solution comprising an antiviral agent.

Abstract: A neuromuscular aid for alleviation and prevention of conditions including muscle cramps and spasms. The neuromuscular aid may be in the form of a packet including a composition including 1 wt % to 15 wt % food grade acid. Instructions for use printed on an exterior of the packet include instructions to retain the composition in the oral cavity of a user for a length of time to alleviate or prevent muscle cramps. An oral treatment method includes administering a composition including 1 wt % to 15 wt % food grade acid to the oral cavity of a subject suffering from muscle cramps and retaining the composition in the oral cavity for a length of time. The composition may be in the form of a gas, a liquid, a solid, a gum, a powder, a thin film strip, a suspension, a colloid, or a gel.

Abstract: In one aspect the present invention features a process for making a tablet comprising the step of applying radiofrequency energy to a powder blend comprising lossy coated particles and at least one pharmaceutically active agent to sinter said powder blend into a tablet, said lossy coated particles comprising a substrate having a Q value of greater than 100 that is at least partially coated with a lossy coating comprising Hydrogenated Starch Hydrolysate.

Abstract: A kit for mucosally administering a metastable supersaturated solution of a pharmaceutical active agent to a human patient includes a first compartment comprising a first composition comprising a pharmaceutical active agent in solution at or below equilibrium solubility, and a second composition comprising an acidic buffer. The first and second compartments maintain separation of the first and second compositions during storage, and allow for mixing of the first and second compositions to form a supersaturated solution above equilibrium solubility of the pharmaceutical active agent for immediate mucosal administration to a human patient. In one embodiment, the second composition comprises an acidic buffer and the supersaturated solution has an acidic pH. Alternatively, the second composition comprises a basic buffer and the supersaturated solution has a basic pH.

Abstract: The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.

Abstract: The present invention discloses a ziyuglycoside II polymer micelle, and it is prepared by following raw/auxiliary materials at predetermined weight ratio: 20 parts of ziyuglycoside II and 100-5000 parts of mPEG-PLA-Phe(Boc). Quality evaluation test indicates that only using mPEG-PLA-Phe(Boc) according to the present invention as carrier materials, the quality of ziyuglycoside II polymer micelle prepared is the best, but using other additional materials can lead to the lowered preparation quality. In the pharmacodynamic experiment, compared with the model group, the ziyuglycoside II micelle of the present invention can significantly increase the amounts of WBC, RBC, PLT, NEUT, and HGB in peripheral blood, and the efficacy is obviously better than the original drug ziyuglycoside II, indicating the ziyuglycoside II polymer micelle of the present invention has a better treatment and/or prevention effects on bone marrow suppression, and can improve the bioavailability of insoluble drug ziyuglycoside II.

Abstract: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.

Abstract: The present invention provides, among other things, methods of delivering mRNA in vivo, including administering to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome such that the administering of the composition results in the expression of the protein encoded by the mRNA in vivo, wherein the liposome comprises a cationic lipid of formula I-c: or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a nutritional and medicinal oral composition for veterinary use, including a core of complete feed extrudate coated with at least one layer of fat. The layer of fat includes at least one medicinal agent which includes: (i) at least one preconditioned active principle in the form of a solution or a suspension of said active principle in an oily liquid, or (ii) at least one preconditioned active principle in the form of waxy granules.

Abstract: A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, said dosage form comprising a pharmacologically active ingredient (A), a free physiologically acceptable acid (B) in an amount of from 0.001 wt.-% to 5.0 wt.-%, based on the total weight of the pharmaceutical dosage form, and a polyalkylene oxide (C) having a weight average molecular weight Mw of at least 200,000 g/mol.

Abstract: The invention is a pharmaceutical composition for the treatment of HIV infection; containing at least one HIV protease inhibitor as an active ingredient, as well as pharmaceutically acceptable excipients with a specific quantitative component ratio. Additionally, the invention belongs to the process of its production and to a treatment method. The inventive pharmaceutical composition has increased bioavailability and improved technological properties, such as durability, plasticity, disintegration, compared to the prototype drug.

Abstract: Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.

Abstract: A capsule excellent in enteric property with the assumption that gelatin is used as a main base material of the capsule coating. An alkali-treated gelatin and carrageenan are contained as base materials of the capsule coating. In the gastric (aqueous) environment, the alkali-treated gelatin which is positively (+) charged coexists with the carrageenan which is negatively (?) charged, and amino groups (NH4+) in the gelatin react with sulfate groups (SO3?) in the carrageenan so that the capsule coating is insolubilized. On the other hand, in the intestinal (aqueous) environment, the alkali-treated gelatin which is negatively (?) charged coexists with the carrageenan which is negatively (?) charged, and the amino groups (NH4+) in the gelatin are repulsive to the sulfate groups (SO3?) in the carrageenan so that the capsule coating quickly disintegrates and dissolves.

Abstract: Methods for forming multiphasic microparticles by using wettability engendered template self-assembly (WETS) techniques are provided. A template is used that defines wettable regions to polar and non-polar liquids and non-wettable regions to polar and non-polar liquids. A first liquid is applied to the template and forms a solid or semi-solid release layer. A second liquid is applied over the release layer to form a solid or semi-solid first layer and a third liquid is applied over the first layer to form a solid or semi-solid second layer. The first layer and the second layer can be released from the template by removing the release layer from the template with a treatment agent to form multiphasic microparticles. Methods for making the templates and multiphasic micro particles are also provided.

Abstract: An acoustically activatable particle of material includes a first substance that includes a component that is a gas 25° C. and atmospheric pressure. A second substance, different from the first substance, encapsulates the first substance to create a droplet or emulsion that is stable at room temperature and atmospheric pressure. At least some of the first substance exists in a gaseous phase at the time of encapsulation of the first substance within the second substance to form a bubble. After formation of the bubble, the bubble is condensed into a liquid phase, which causes the bubble to transform into the droplet or emulsion having a core consisting of a liquid. The droplet or emulsion is an activatable phase change agent having a core consisting of a liquid at 25° C. and atmospheric pressure. The first substance has a boiling point below 25° C. at atmospheric pressure.

Abstract: A nanocapsule includes a liquid hydrophobic care including an essential oil, and a shell encapsulating the core. The shell includes a copolymer having repeating units of Formula (I) and (II) wherein X, L1, R1, R2, y, and p are as described herein. A dispersion is also disclosed, wherein the dispersion includes a plurality of nanocapsules. The nanocapsules described herein are particularly useful for the treatment of bacterial biofilms.

Abstract: A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer.

Abstract: A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer.

Abstract: Provided are a pharmaceutical composition including geraniol or a pharmaceutically acceptable salt thereof as an active ingredient for use in preventing or treating diabetes mellitus, a method of preventing or treating diabetes mellitus or a complication due to diabetes mellitus of an individual, in which the method includes administering the individual with a pharmaceutical composition comprising geraniol or a pharmaceutically acceptable salt thereof as an active ingredient and inducing an olfactory stimulation to the individual using the pharmaceutical composition, and a screening method of an antidiabetic agent that may include contacting a cell expressing an olfactory receptor with a test material; measuring a level of expression of glucagon-like peptide-1 (GLP-1) secreted from the cell; and determining the test material, when the test material promotes expression of GLP-1, as a candidate material of an antidiabetic agent.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating autoimmune diseases having cedrol or a pharmaceutically acceptable salt thereof as an active ingredient. Particularly, the cedrol or the derivative thereof of the present invention inhibits the expression of IL-17A, and in particular, cedrol, cedryl acetate, and cedrene exhibit the effect of delaying the outbreak of psoriasis and treating thereof in a psoriasis animal model. Therefore, these compounds can be used for the treatment of autoimmune diseases mediated by IL-17.